The Preclinical Stage and Clinical Stage will be open to entrants at more advanced stages of combination product development. In order to compete in the Preclinical Stage or Clinical Stage, prospective entrants will be required to submit declarations of intent as described in the respective overview sections of the about page. The Preclinical Stage and Clinical Stage timelines are subject to change, and will be updated prior to the launch of those stages.
Timeline
Concept Stage: Development plans
Concept Stage launched
March 28, 2024
Prize information and submission requirements announced.
Virtual information session
April 18, 2024
Webinar held covering prize details and a Q&A with the BARDA team.
Concept Stage submissions opened
August 1, 2024
Eligible entrants could submit development plans from 9 a.m. ET.
Concept Stage submissions closed
October 3, 2024
Eligible entrants must submit development plans before 4:59 p.m. ET.
We are here
Concept Stage evaluation
October-November 2024
Concept Stage judging panel will evaluated submissions.
Concept Stage winner announcement
January 2025
Up to four Concept Stage winners will receive a share of the $8 million Concept Stage prize pool.
Specific dates and details will be published prior to the Preclinical Stage launch.
Preclinical Stage: Investigational New Drug (IND) application enabling studies
Preclinical Stage launch and declaration of intent period opens
Early 2025
Preclinical Stage begins and prospective entrants can submit declarations of intent.
Preclinical Stage submissions open
Early 2025
Prospective entrants accepted to the Preclinical Stage can submit technical papers.
Preclinical Stage submission deadline
Late 2026
Eligible entrants must submit technical papers before the deadline, to be announced.
Preclinical Stage winner announcements
Late 2026
Up to three Preclinical Stage winners are expected to have received a share of the $21 million Preclinical Stage prize pool.
Specific dates and details will be published prior to the Clinical Stage launch.
Clinical Stage: Phase I clinical trials
Clinical Stage launch
Mid 2025
Clinical Stage begins.
Clinical Stage declarations of intent open
Mid 2025
Prospective entrants can submit declarations of intent.
Clinical Stage submissions open
Mid 2025
The prize platform will open for eligible entrants to submit development plans.
Clinical Stage evaluation periods begin
Mid 2026
Clinical Stage judging panel will begin to evaluate submissions. Multiple evaluation periods will be opened and closed during the Clinical Stage.
Clinical Stage submission deadline
Early 2028
Eligible entrants must submit technical papers before the deadline, to be announced.
Clinical Stage evaluation periods end
Mid 2028
Clinical Stage judging panel will conclude the final evaluation period.
Clinical Stage winner announcements
Late 2028
Up to two Clinical Stage winners are expected to have received a share of the $21 million Clinical Stage prize pool.